Takeda's Vedolizumab Demonstrated Robust Clinical Effectiveness and Safety in...
OSAKA Japan Oct. 17 2016 PRNewswire Takeda Pharmaceutical Company Limited TSE 4502 "Takeda" is presenting data on the realworld effectiveness and safety of vedolizumab in patients with moderately to...
View ArticleCelgene Announces Oral GED0301 Phase 1b Results On Crohn's Disease
SUMMIT dpaAFX Celgene International Srl a whollyowned subsidiary of Celgene Corp. CELG announced that data from a randomized doubleblind multicenter exploratory phase 1b study evalu...
View ArticleCelgene Crohn's Drug Benefit Supported by Image Data in Trial 36 minutes ago
Celgene Corp.&39;s experimental pill for Crohn&39;s disease helped more patients than analysts expected reinforcing positive results of an earlier study and likely boosting investors&39;...
View ArticleCelgene Crohn's Pill Data Unspectacular but Perhaps Good Enough
Click to view a price quote on CELG. Click to research the Drugs industry.
View ArticleTiGenix Announces Orphan Drug Designation ODD for Cx601 in Switzerland
PRESS RELEASE TiGenix Announces Orphan Drug Designation ODD for Cx601 in Switzerland Leuven BELGIUM October 17 2016 0700h CET TiGenix NV Euronext Brussels TIG an advanced biopharmaceutical company...
View ArticleSoligenix to Receive $530000 in NonDilutive Funding Through New Jersey...
PRINCETON N.J. Oct. 17 2016 PRNewswire Soligenix Inc. OTCQB SNGXD Soligenix or the Company a latestage biopharmaceutical company focused on developing and commercializing products to treat rare...
View ArticleCelgene trial displays promising results for Crohns disease alternative...
Celgene International part of Celgene Corporation has released the results from a Phase Ib trial showing improvement in patients suffering from Crohns disease.read more
View ArticleTakeda Presents RealWorld Vedolizumab Data in Ulcerative Colitis and Crohn's...
DEERFIELD Ill. Oct. 17 2016 PRNewswire Today Takeda Pharmaceuticals U.S.A. Inc. "Takeda" announced data highlighting the effectiveness and safety profile of vedolizumab for the treatment of adults with...
View ArticleImmune Pharmaceuticals Announces Formation of Management Team for Maxim...
NEW YORK Oct. 17 2016 PRNewswire Immune Pharmaceuticals Inc. NASDAQ IMNP "Immune" announced today that it has entered into a consulting agreement with Joseph V. Pergolizzi Jr. MD. Dr. Pergolizzi will...
View ArticleOral GED0301 Phase 1b Results Show Clinical Remission and Endoscopic Response...
Sunday October 16th 2016 at 1111pm UTC Clinical improvement observed early with highest clinical response and remission rates in the 12week treatment group Endoscopic improvement seen across all...
View ArticleEarly Data for Celgenes Oral Crohns Drug Gets Mixed Reaction
Celgene late Sunday provided more details on one of the more important drugs in its pipeline a pill the Summit NJ company is developing for inflammatory bowel disease. Analysts on Wall Street are mixed...
View ArticleCelgene Announces Results from EarlyStage Study of Investigational Crohns...
VIENNA&8211;BUSINESS WIRE&8211;Celgene International Srl a whollyowned subsidiary ofÂCelgene Corporation NASDAQ CELGÂtoday announced that data from a randomized doubleblind multicenter...
View ArticleResearchers identify 2 distinct genetic subtypes in Crohns disease patients.
Crohn&8217;s disease a common inflammatory disorder of the intestinal tract can have devastating consequences for a patient&8217;s quality of life. Although people with the disease are...
View ArticleJohnson & Johnson Reports 2016 ThirdQuarter Results
NEW BRUNSWICK N.J. Oct. 18 2016 PRNewswire Johnson & Johnson NYSE JNJ today announced sales of $17.8 billion for the third quarter of 2016 an increase of 4.2 as compared to the third quarter of...
View ArticleSoligenix Announces Publication of its Phase 2 Clinical Trial Results of...
PRINCETON N.J. Oct. 18 2016 PRNewswire Soligenix Inc. OTCQB SNGXD Soligenix or the Company a latestage biopharmaceutical company focused on developing and commercializing products to treat rare...
View ArticleMEDIBEACON Inc. Collaborates with Washington University in $1.1 Million Grant...
ST. LOUIS Oct. 18 2016 PRNewswire MediBeacon Inc. announced today that it would collaborate with scientists at Washington University School of Medicine in St. Louis in a research project aimed at...
View ArticleRedHill Biopharma Announces Allowance of a Patent in Japan Supporting RHB104...
RedHill has received from the Japan Patent Office a Notice of Allowance for a new patent covering RHB104 for multiple sclerosis MS expected to be valid until 2032 once grantedRedHills robust RHB104...
View ArticleSenator Edwards Visits BioTherapeutics Inc.
Senator John Edwards is learning more about the biotech industry firsthand. He visited BioTherapeutics Inc. BTI to tour their facility at the VT Corporate Research Center and learn more about the...
View ArticleCrohn's & Colitis Foundation Of America Launches Revamped Website Experience...
NEW YORK Oct. 18 2016 PRNewswireUSNewswire Today the Crohn's & Colitis Foundation of America CCFA unveiled its new digital website experience for one of its signature fundraising programs Take...
View Article